A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors Including RET Fusion-Positive Solid Tumors Medullary Thyroid Cancer and Other Tumors With RET Activation (LIBRETTO-001) | NYU Langone Health

Go Back to All Clinical Trials

A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors Including RET Fusion-Positive Solid Tumors Medullary Thyroid Cancer and Other Tumors With RET Activation (LIBRETTO-001)